|Trade names||Vabomere, Vaborem, others|
|Main uses||Urinary tract infections, complicated abdominal infections, hospital-acquired pneumonia|
|Side effects||Headache, inflammation at site of injection, nausea, diarrhea, liver inflammation, low blood potassium|
|Defined daily dose||not established|
Meropenem/vaborbactam, sold under the trade name Vabomere among others, is a combination medication used to treat complicated urinary tract infections, complicated abdominal infections, and hospital-acquired pneumonia. It contains meropenem, a β-lactam antibiotic, and vaborbactam, a β-lactamase inhibitor. It is given by injection into a vein.
Common side effects include headache, inflammation at the site of injection, nausea, diarrhea, liver inflammation, and low blood potassium. Severe side effects may include anaphylaxis, seizures, and Clostridium difficile-associated diarrhea. It is unclear if use during pregnancy is safe. Meropenem works by blocking the construction of the bacterial cell wall while vaborbactam blocks the breakdown of meropenem by some β-lactamases.
The combination was approved for medical use in the United States in 2017 and Europe in 2018. It is on the World Health Organization's List of Essential Medicines. In the United States it costs about US$1,126 per day as of 2019.
It is used to treat complicated urinary tract infections, complicated abdominal infections, and hospital-acquired pneumonia.
In a study of 545 adults with complicated urinary tract infections, 98 percent of adults treated with Vabomere compared with about 94 percent of adults treated with piperacillin/tazobactam were cured defined as improvement in symptoms and a negative urine culture. About seven days after completing treatment, roughly 77 percent of adults treated with Vabomere compared with about 73 percent of those treated with piperacillin/tazobactam had resolved symptoms and a negative urine culture.
Successful bacteremia clearance in a child has been reported using a meropenem-vaborbactam dose of 40 mg/kg every 6 hours given over 3 hours. It attained 100% of meropenem serum concentrations above the minimum inhibitory concentration for at least 40% of the dosing interval.
The defined daily dose is not established.
The most common adverse reactions were headache, infusion site reactions and diarrhea. Serious risks include allergic reactions and seizures and Meropenem/vaborbactam should not be used in people with severe allergic reactions to penicillins.
Rempex Pharmaceuticals developed the drug. It was designated as a "qualified infectious disease product" under the Generating Antibiotic Incentives Now (GAIN) title of the FDA Safety and Innovation Act and therefore received priority review. In August 2017, the US Food and Drug Administration approved it to treat complicated urinary tract infections and pyelonephritis.
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 "Vabomere (combination) Monograph for Professionals". Drugs.com. Archived from the original on 6 November 2019. Retrieved 6 November 2019.
- ↑ 2.0 2.1 2.2 2.3 "Vaborem". European Medicines Agency. 24 September 2018. Archived from the original on 6 November 2019. Retrieved 6 November 2019.
- ↑ 3.0 3.1 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 1 July 2021. Retrieved 10 September 2020.
- ↑ "Meropenem / vaborbactam (Vabomere) Use During Pregnancy". Drugs.com. Archived from the original on 6 November 2019. Retrieved 6 November 2019.
- ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ↑ "Vabomere Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 6 November 2019. Retrieved 6 November 2019.
- ↑ 7.0 7.1 7.2 "FDA approves new antibacterial drug" (Press release). Food and Drug Administration (FDA). 29 August 2017. Archived from the original on 23 April 2019. Retrieved 14 September 2017. This article incorporates text from this source, which is in the public domain.
- ↑ Hanretty AM, Kaur I, Evangelista AT, Moore WS, Enache A, Chopra A, Cies JJ (December 2018). "Pharmacokinetics of the Meropenem Component of Meropenem-Vaborbactam in the Treatment of KPC-Producing Klebsiella pneumoniae Bloodstream Infection in a Pediatric Patient". Pharmacotherapy. 38 (12): e87–e91. doi:10.1002/phar.2187. PMID 30300440.
- Drug Information from the NIH Archived 6 November 2019 at the Wayback Machine
- Pages using duplicate arguments in template calls
- Use dmy dates from September 2019
- Articles with invalid date parameter in template
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Webarchive template wayback links
- Combination antibiotics
- World Health Organization essential medicines